Suchergebnisse - "Chen, Gongyan"

PubPharm (102)

1

Efficacy and safety of utidelone for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer who have failed standard second-line treatment : A phase 2 clinical trial (BG01-1801)

enthalten in: Cancer pathogenesis and therapy | 2024

von Shi, Y. | Chen, G. | Zhao, Y. | +2

2

First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302) : a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial

enthalten in: The Lancet. Respiratory medicine | 2024

von Zhong, H. | Sun, S. | Chen, J. | +41

3

HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non-Small Cell Lung Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Jiang, T. | Jin, Q. | Wang, J. | +38

CommentIn: Clin Cancer Res. 2023 Dec 1;29(23):4706-4708. - PMID 37756560

4

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer : a multicentre, open-label, randomised phase 3 study

enthalten in: The Lancet. Respiratory medicine | 2023

von Lu, S. | Zhou, J. | Jian, H. | +41

CommentIn: Lancet Respir Med. 2023 Oct;11(10):857-859. - PMID 37244264

5

Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation : A pooled analysis of two clinical studies

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2023

von Yang, S. | Wu, S. | Zhao, Y. | +54

6

Third-line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases : A post hoc analysis of ALTER1202, a randomized, double-blind phase 2 study

enthalten in: Cancer innovation | 2023

von Cheng, Y. | Wang, Q. | Li, K. | +8

7

Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC : Extended Follow-Up of CameL Phase 3 Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Zhou, C. | Chen, G. | Huang, Y. | +54

8

Third‐line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases : A post hoc analysis of ALTER1202, a randomized, double‐blind phase 2 study

enthalten in: Cancer Innovation | 2023

von Cheng, Y. | Wang, Q. | Li, K. | +8

9

Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy

enthalten in: Cancer communications (London, England) | 2022

von Wu, F. | Jiang, T. | Chen, G. | +37

10

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG) : a multicentre, double-blind, randomised phase 3 study

enthalten in: The Lancet. Respiratory medicine | 2022

von Shi, Y. | Chen, G. | Wang, X. | +20

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]